Kura Oncology (KURA)

$11.06 +0.27 (2.50%)
Market Cap 938.92M
Revenue (ttm) 53.88M
Net Income (ttm) -173.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -322.90%
Debt to Equity Ratio 0.04
Volume 553,100
Avg Vol 2,005,802
Day's Range N/A - N/A
Shares Out 87.02M
Stochastic %K 86%
Beta 0.21
Analysts Strong Sell
Price Target $33.00

Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC;...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 500 8800
Address:
12730 High Bluff Drive, Suite 400, San Diego, United States
JFais
JFais Dec. 25 at 1:46 PM
$KURA (L) From Q4 DCA portfolio update
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 25 at 4:46 AM
$KURA Current Stock Price: $11.06 Contracts to trade: $10 KURA Jan 16 2026 Call Entry: $0.90 Exit: $1.32 ROI: 47% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
sprmn
sprmn Dec. 25 at 3:03 AM
$KURA fellow retailers: The 2026 data readouts are critical because Kyowa Kirin holds an opt-in right for Kura’s solid tumor programs. If the 2026 data for darlifarnib (KO-2806) in RCC or Lung Cancer (with adagrasib) looks "best-in-class," it will likely be the catalyst for Kyowa Kirin to either exercise their opt-in or move toward a full acquisition of Kura Oncology.
0 · Reply
BIGT80
BIGT80 Dec. 24 at 8:44 PM
$KURA
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 8:02 PM
Enter: $KURA Calls Strike Price: $12 Expiry Date: JAN 16 2026 Buy in Price: $0.35 - $0.37 Sell Price: $0.79 Profit : +125% (Turn every $1 into $2.25) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
sprmn
sprmn Dec. 24 at 4:03 PM
$KURA $XBI 🚀🚀🚀
0 · Reply
sprmn
sprmn Dec. 24 at 12:37 PM
$KROS $KURA $TNXP $XBI where is the crying bear 🐻?
0 · Reply
sprmn
sprmn Dec. 24 at 12:14 PM
$KURA
0 · Reply
RocketRiderRick
RocketRiderRick Dec. 24 at 10:23 AM
$KURA Current positioning will be tested as measurable traction replaces episodic catalyst-driven interest. Confidence improves only with repeatable results.
0 · Reply
sprmn
sprmn Dec. 24 at 10:09 AM
$KURA 🚀🚀🚀🚀🚀🚀🚀
0 · Reply
Latest News on KURA
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript

Dec 8, 2025, 5:17 PM EST - 16 days ago

Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

Dec 8, 2025, 10:30 AM EST - 16 days ago

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

Kura Oncology: A Cautious Buy

Dec 4, 2025, 8:08 AM EST - 21 days ago

Kura Oncology: A Cautious Buy

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

Dec 3, 2025, 8:32 AM EST - 22 days ago

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data

Dec 2, 2025, 6:36 PM EST - 22 days ago

Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

Dec 2, 2025, 8:02 AM EST - 23 days ago

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

Nov 25, 2025, 5:16 PM EST - 4 weeks ago

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript

Nov 19, 2025, 5:23 PM EST - 5 weeks ago

Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Nov 13, 2025, 10:51 AM EST - 5 weeks ago

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

US FDA approves Kura Oncology's blood cancer therapy

Nov 13, 2025, 10:32 AM EST - 5 weeks ago

US FDA approves Kura Oncology's blood cancer therapy

Kura Oncology to Participate in Upcoming Investor Conference

Nov 12, 2025, 4:05 PM EST - 6 weeks ago

Kura Oncology to Participate in Upcoming Investor Conference

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2025, 7:30 AM EST - 6 weeks ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology, Inc. (KURA) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 3:46 PM EST - 7 weeks ago

Kura Oncology, Inc. (KURA) Q3 2025 Earnings Call Transcript

Kura Oncology Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 6:31 AM EST - 7 weeks ago

Kura Oncology Reports Third Quarter 2025 Financial Results

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

Nov 3, 2025, 4:02 PM EST - 7 weeks ago

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

Nov 3, 2025, 9:14 AM EST - 7 weeks ago

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

Kura Oncology's Ziftomenib Poised For Differentiation

Nov 2, 2025, 9:00 AM EST - 7 weeks ago

Kura Oncology's Ziftomenib Poised For Differentiation

Kura Oncology to Report Third Quarter 2025 Financial Results

Oct 28, 2025, 4:01 PM EDT - 2 months ago

Kura Oncology to Report Third Quarter 2025 Financial Results

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Oct 24, 2025, 7:02 AM EDT - 2 months ago

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript

Oct 18, 2025, 6:56 PM EDT - 2 months ago

Kura Oncology, Inc. (KURA) Discusses Clinical Updates on Farnesyl Transferase Inhibitor Programs and Combination Therapies in Oncology Transcript

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 18, 2025, 3:23 AM EDT - 2 months ago

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript

Oct 1, 2025, 5:02 PM EDT - 3 months ago

Kura Oncology, Inc. (KURA) Presents at UBS Virtual Oncology Day Transcript

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Oct 1, 2025, 7:01 AM EDT - 3 months ago

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

Sep 29, 2025, 4:01 PM EDT - 3 months ago

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

Sep 25, 2025, 5:18 PM EDT - 3 months ago

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy

Sep 19, 2025, 11:03 AM EDT - 3 months ago

Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy

Kura Oncology, Inc. - Special Call

Sep 16, 2025, 10:53 PM EDT - 3 months ago

Kura Oncology, Inc. - Special Call

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Sep 16, 2025, 4:01 PM EDT - 3 months ago

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 4:44 PM EDT - 3 months ago

Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Sep 3, 2025, 8:02 AM EDT - 4 months ago

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Kura Oncology to Participate in Three Upcoming Investor Conferences

Aug 28, 2025, 7:30 AM EDT - 4 months ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 10:46 PM EDT - 4 months ago

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Kura Oncology Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Kura Oncology Reports Second Quarter 2025 Financial Results

Kura Oncology to Report Second Quarter 2025 Financial Results

Jul 31, 2025, 7:30 AM EDT - 5 months ago

Kura Oncology to Report Second Quarter 2025 Financial Results

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Jul 2, 2025, 12:09 AM EDT - 6 months ago

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Jun 12, 2025, 7:30 AM EDT - 7 months ago

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

Jun 2, 2025, 6:00 PM EDT - 7 months ago

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Jun 1, 2025, 7:00 PM EDT - 7 months ago

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 22, 2025, 5:30 PM EDT - 7 months ago

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

May 14, 2025, 10:00 AM EDT - 8 months ago

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 6, 2025, 7:30 AM EDT - 8 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

May 1, 2025, 8:48 PM EDT - 8 months ago

Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript

Kura Oncology Reports First Quarter 2025 Financial Results

May 1, 2025, 4:05 PM EDT - 8 months ago

Kura Oncology Reports First Quarter 2025 Financial Results

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Apr 28, 2025, 7:30 AM EDT - 8 months ago

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Kura Oncology to Report First Quarter 2025 Financial Results

Apr 24, 2025, 7:30 AM EDT - 8 months ago

Kura Oncology to Report First Quarter 2025 Financial Results

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Apr 8, 2025, 7:30 AM EDT - 9 months ago

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Apr 1, 2025, 7:30 AM EDT - 9 months ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

Mar 26, 2025, 7:30 AM EDT - 9 months ago

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity

Mar 4, 2025, 10:12 AM EST - 10 months ago

Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity

Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:46 AM EST - 10 months ago

Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript

JFais
JFais Dec. 25 at 1:46 PM
$KURA (L) From Q4 DCA portfolio update
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 25 at 4:46 AM
$KURA Current Stock Price: $11.06 Contracts to trade: $10 KURA Jan 16 2026 Call Entry: $0.90 Exit: $1.32 ROI: 47% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
sprmn
sprmn Dec. 25 at 3:03 AM
$KURA fellow retailers: The 2026 data readouts are critical because Kyowa Kirin holds an opt-in right for Kura’s solid tumor programs. If the 2026 data for darlifarnib (KO-2806) in RCC or Lung Cancer (with adagrasib) looks "best-in-class," it will likely be the catalyst for Kyowa Kirin to either exercise their opt-in or move toward a full acquisition of Kura Oncology.
0 · Reply
BIGT80
BIGT80 Dec. 24 at 8:44 PM
$KURA
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 8:02 PM
Enter: $KURA Calls Strike Price: $12 Expiry Date: JAN 16 2026 Buy in Price: $0.35 - $0.37 Sell Price: $0.79 Profit : +125% (Turn every $1 into $2.25) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
sprmn
sprmn Dec. 24 at 4:03 PM
$KURA $XBI 🚀🚀🚀
0 · Reply
sprmn
sprmn Dec. 24 at 12:37 PM
$KROS $KURA $TNXP $XBI where is the crying bear 🐻?
0 · Reply
sprmn
sprmn Dec. 24 at 12:14 PM
$KURA
0 · Reply
RocketRiderRick
RocketRiderRick Dec. 24 at 10:23 AM
$KURA Current positioning will be tested as measurable traction replaces episodic catalyst-driven interest. Confidence improves only with repeatable results.
0 · Reply
sprmn
sprmn Dec. 24 at 10:09 AM
$KURA 🚀🚀🚀🚀🚀🚀🚀
0 · Reply
tltisbae
tltisbae Dec. 23 at 7:58 PM
$KURA one of my best trades this year, wondering after the new year we have some buyout news?
1 · Reply
sprmn
sprmn Dec. 23 at 11:40 AM
$KROS $KURA $TNXP $XBI where is the bear? 🐻
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 6:19 AM
$KURA RSI: 51.30, MACD: -0.1078 Vol: 0.77, MA20: 11.10, MA50: 10.61 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 23 at 2:17 AM
Enter: $KURA Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.76 - $1.00 Sell Price: $1.64 Profit : +116% (Turn every $1 into $2.16) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
sprmn
sprmn Dec. 23 at 1:37 AM
$XBI where is the bear? 🐻 $KURA $KROS $TNXP
0 · Reply
dixiebull
dixiebull Dec. 22 at 9:43 PM
$KURA long time and FDA approval really didn't do much, we scaled off some gains and some added back on
1 · Reply
dixiebull
dixiebull Dec. 22 at 9:41 PM
$MU almost got 280 here, so if that breaks we can see 282.50 to 283 and 285 $POET got 7.90 off prior watchlist, see if 7.50 holds for a break of 8 to 8.50 $RZLV ran to get 3 and pulled back, see if 2.85 holds for 3 to 3.15 and 3.25 to 3.35 $KURA swing went from 10 to 11.31 today, see if 11 holds now for a move to 11.50 and 12
0 · Reply
quickaspeter
quickaspeter Dec. 22 at 8:03 PM
$KURA Let’s go…$20+ is coming! 💥🚀💰💰💰
0 · Reply
BIGT80
BIGT80 Dec. 22 at 7:27 PM
$KURA strong like bull!
0 · Reply
laborsaamericana1951
laborsaamericana1951 Dec. 22 at 5:48 PM
$KURA
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 22 at 5:05 PM
$KURA
0 · Reply
sprmn
sprmn Dec. 22 at 4:03 PM
$KURA Jim Cramer Effect!!!!
0 · Reply